Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SNSE

SNSE - Sensei Biotherapeutics, Inc. Stock Price, Fair Value and News

$10.08+0.14 (+1.41%)
Market Closed

50/100

SNSE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

50/100

SNSE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$11.08

Target 3M

$10.68

Target 6M

$10.81

SNSE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNSE Price Action

Last 7 days

7.1%

Last 30 days

12.1%

Last 90 days

6.7%

Trailing 12 Months

2.4%

SNSE RSI Chart

SNSE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNSE Valuation

Market Cap

12.7M

Price/Earnings (Trailing)

-0.53

Price/Sales (Trailing)

8.27

Price/Free Cashflow

-0.57

SNSE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$11.08

Target 3M

$10.68

Target 6M

$10.81

SNSE Fundamentals

SNSE Revenue

Revenue (TTM)

1.5M

Rev. Growth (Yr)

-51.1%

Rev. Growth (Qtr)

-9.97%

SNSE Earnings

Earnings (TTM)

-24.1M

Earnings Growth (Yr)

37.01%

Earnings Growth (Qtr)

7.44%

SNSE Profitability

Return on Equity

-104.92%

Return on Assets

-87.5%

Free Cashflow Yield

-176.16%

SNSE Investor Care

Shares Dilution (1Y)

0.30%

Diluted EPS (TTM)

-19.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.2M1.8M1.5M0
20243.4M3.1M2.9M2.5M
20232.4M3.0M3.4M3.6M
20221.0M1.3M1.5M1.8M
2021000800.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Sensei Biotherapeutics, Inc.

SNSE
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEsenseibio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES23

Sensei Biotherapeutics, Inc. Frequently Asked Questions

SNSE is the stock ticker symbol of Sensei Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sensei Biotherapeutics, Inc. is 12.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SNSE's fair value in chart for subscribers.

The fair value guage provides a quick view whether SNSE is over valued or under valued. Whether Sensei Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Sensei Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNSE.

As of Wed Jan 28 2026, SNSE's PE ratio (Price to Earnings) is -0.53 and Price to Sales (PS) ratio is 8.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNSE PE ratio will change depending on the future growth rate expectations of investors.